MCM
BPMC

Moore Capital Management’s Blueprint Medicines BPMC Stock Holding History

Moore Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$2.56M – 629
2025
Q2 		$2.56M Buy
+20,000
New +$2.08M 0.03% 297
2022
Q4 		– Sell
-226,782
Closed -$14.9M – 560
2022
Q3 		$14.9M Buy
+226,782
New +$14.6M 0.35% 51
2022
Q1 		– Sell
-38,654
Closed -$4.14M – 756
2021
Q4 		$4.14M Sell
38,654
-126,415
-77% -$13.2M 0.08% 260
2021
Q3 		$17M Sell
165,069
-29,114
-15% -$2.71M 0.26% 80
2021
Q2 		$17.1M Buy
194,183
+77,272
+66% +$7.08M 0.24% 89
2021
Q1 		$11.4M Sell
116,911
-88,543
-43% -$8.84M 0.14% 115
2020
Q4 		$23M Buy
205,454
+85,802
+72% +$9.04M 0.25% 61
2020
Q3 		$11.1M Buy
119,652
+94,652
+379% +$7.29M 0.21% 97
2020
Q2 		$1.95M Buy
+25,000
New +$1.69M 0.05% 194
2018
Q1 		– Sell
-35,000
Closed -$2.64M – 256
2017
Q4 		$2.64M Buy
+35,000
New +$2.46M 0.05% 178

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Moore Capital Management's BPMC Position: Q3 2025 in Review

Moore Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 20,000 shares — an estimated $2.56M sold.

Moore Capital Management first reported a position in BPMC in Q4 2017 and held it in 10 quarters. The position peaked at $23M in Q4 2020. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Moore Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Moore Capital Management sold 20,000 Blueprint Medicines shares in Q3 2025, an estimated $2.56M.
  • Moore Capital Management first reported a position in Blueprint Medicines in Q4 2017 and held it in 10 quarters.
  • Moore Capital Management's Blueprint Medicines position peaked at $23M in Q4 2020.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Moore Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.